Inflammatory myopathies

Longitudinal changes in nailfold videocapillaroscopy findings differ by myositis-specific autoantibody in idiopathic inflammatory myopathy

Rheumatology (Oxford)Published Retrospective cohort study

Authors' conclusion

The results of this study demonstrate that longitudinal changes in NVC findings may vary depending on myositis-specific Ab expression.

Study context

Population
IIM patients expressing myositis-specific autoantibodies (anti-ARS, anti-TIF1, anti-MDA5), single site
Participants
71 patients
Exposure
Longitudinal nailfold videocapillaroscopy (NVC) changes in IIM by myositis-specific autoantibody: anti-MDA5 vs anti-TIF1 vs anti-ARS
  • Anti-MDA5n = 25
  • Anti-TIF1n = 24
  • Anti-ARSn = 22
Outcome
Change in NVC findings (giant, enlarged and reduced capillaries, haemorrhages, ramification, disorganization, capillary loss) from baseline to after disease activity stabilization
Follow-up
After disease activity stabilization
Methodological detailssingle-centre, observational
  • Single-centre
  • Observational

Main finding

As reported in the abstract

Longitudinal change in NVC findings, baseline to after stabilization
Enlarged capillaries improved after stabilization in anti-MDA5
P < 0.0001
Reduced capillaries improved after stabilization in anti-MDA5
P < 0.05
Significant reduction in haemorrhages in all three groups
P < 0.0001 for each group

Observational data: associations, not effects.

Further findings

Reduced capillaries at baseline — Anti-TIF1 vs Anti-MDA5

P < 0.0001

OutcomeAnti-MDA5Anti-TIF1Anti-ARSP value
Enlarged capillaries at baselineAnti-TIF1 vs Anti-ARS— not stated in the abstract88%55%P < 0.05
Reduced capillaries at baselineAnti-TIF1 vs Anti-ARSP < 0.0005

— not stated in the abstract

Enlarged capillaries at baseline

Frequency different among the three groups

Original publication

Longitudinal changes in nailfold videocapillaroscopy findings differ by myositis-specific autoantibody in idiopathic inflammatory myopathy. Rheumatology (Oxford). Published 22 July 2022. doi:10.1093/rheumatology/keac401

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.